The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ok - that was actually more informative than MH's presentation. There were a number of points I was really glad to hear:
1. He acknowledged that jCyte had good results in their Ph2b but he expects to beat them with the 2M cell dose.
2. He recognised that COVID could derail some of the trial sites so they are planning on more for contingency so that the trial is not delayed.
3. They expect to revisit partnering for the hRPC program next summer . The timescales make sense given that the primary endpoint in the extension study is at 6 months (see clinical trials.gov). Dosing all the patients by Q1 next year and results are evident after 30 - 60 days.
4. Exosome collaborations are ongoing but they are playing things close to their chest (they are probably under NDA anyway) but at some point news will break.
Not sure how I missed this at the time, but please see link below for presentation at H. C. Wainwright 22nd Annual Global Investment Conference on 15th Sept. Hopefully the link works.
https://wsw.com/webcast/hcw7/rene/1600890
or via Rene website: http://www.reneuron.com/presentations-list/h-c-wainwright-22nd-annual-global-investment-conference-virtual/
Olav discusses perceived benefits of sub-retinal procedure towards the middle of the video, as well as touching on the Jcyte study in general.
Also makes a very interesting comment at the end regarding CTX trial (and reasoning for licencing the trial):
"there's nothing wrong with the programme or the drug, but we have a huge opportunity on the retinitis pigmentosa side and we'd rather put our resources behind that."
I do hope so.. good that he's stayed the test of time......
Oh well, no rns. I'm sure MH will still manage to find something to titillate us with in the presentation this evening.
I agree with your sentiments, Phil. I think a RNS tomorrow is unlikely and MH's presentation will come amd go with little effect on the share price because he cannot provide market moving infomation in that forum.
Most LTH know that a significant announcement around RP will start the share price on the same trajectory as when they announced the early phase2a results.
An announcent on exosome collaboration success could be even more significant because it will mean that Rene have been able to carry a third party compound across the blood-brain barrier. This ia a holy grail of the pharma industey and would be very significant. RENE would have a vehicle that would be in demand by a multitude of biotech amd big pharma players. It would almost certainly allow RENE to negotiate research/developmwnt milestone payments from partners in the near term and would likely be transformative.
Of course, as a.holder, I could be somewhat biased!
Hi Phil
My 10k was bought in two 5k lumps one at 94p the other at 95.25p.
I couldn't buy the whole 10k in one go below 97p.
Another committed RENE warrior bought the 10k....
Anyway I'm happy with my holding just wanting to hear the good news about the RP trial or positive lab results for Exosomes, either will do.
Chester.
I saw that 10k buy and wondered if it might be you, chester. With regards to the price action tomorrow, the current price has bounced off medium/long term support, consolidated and looked relatively solid, so I'm not completely sure the 'no RNS' scenario will necessarily result in anything particularly negative. Ultimately it's a scenario that we have managed to conjure up on this board because I spotted a scheduled event/presentation. How many RENE investors actually read this board, and how many readers would pay attention to our conjecture is another thing all together. That said, a game changing RNS would be nice.
So now it looks like a binary play....
News tomorrow in the form of an RNS update before MH presents... Price Over £1.00 +
Or
No update with the same 'In a few months time' message..... Price heading for 80p -
I'm just stating the obvious but I really do want that RNS to be there in the morning as I've just topped up by 10,000 shares.
Fingers crossed........GLA
Chester.
I suspect we really have found a support level after slowly declining from a high of £3. Most sellers have been flushed out and those that remain are resigned to holding at least until we finally get some good commercial news!
I expect MH to shed more light on the RP trial but unless there is an RNS released prior to his presentation, he will not be giving away anything relating to efficacy. The same is true of the exosome collaborations. No doubt, he will again make use of his favourite phrase "in the coming months" which I personally find intensley annoying because it means nothing.
Anyway, we live in hope!
my guess is news on RP and exosomes/cancer treatment.... in the current climate I'd be surprised if we hear any news on stroke... thats my guess for what its worth.
Is news about to land ?
Yesterday we had a large sell 74k @ 90.5p so you would expect the MMs to have plentiful stock to cover a 10,000 purchase but here's the thing : I've been quoted 90p to Sell 10k but 97p if I want to Buy.
So why such a large spread which shouts 'we have no stock we want to part with' and only will, if your prepared to pay 97p.
Why such a lift in the price when they obviously do have more than enough stock from yesterdays 74k sale.
Therefore I am Intrigued to see if there is something behind this.
MH presentation 6.00pm on Thursday, is there an RNS coming with an update ?
Chester.